ZGZhongying Guo

Zhongying Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhongying Guo has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Bing Zhong

    Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China

    1 shared publication
  • Chao Yang

    Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China

    1 shared publication
  • Dongsheng Pei

    Department of Pathology, School of Basic Medical Sciences, Xuzhou Medical University, Xuzhou, China

    1 shared publication
  • Guangbo Fu

    Department of Urology, The Affiliated Huaian No.1 People’s Hospital, Nanjing Medical University, Huaian, China

    1 shared publication
  • Hengbing Wang

    Department of Urology, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian City, China

    1 shared publication
  • Hesong Jiang

    Department of Urology, The Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China

    1 shared publication

Latest Publications

  • PAK5 potentiates slug transactivation of N-cadherin to facilitate metastasis of renal cell carcinoma

    by Xu Liu, Yao-Jie Pan, Meng-Jie Kang, Xin Jiang, Zhong-Ying Guo, Dong-Sheng Pei


  • Open Access

    Solitary Fibrous Tumor of the Prostate Shown on FAPI PET/CT

    by Tianshuo Mm Yang, Ronghua Mm Zhu, Zhongying Guo, Xiaobing Niu, Weijing Tao

    Solitary fibrous tumors are fibroblast tumors that occur mainly in the peritoneum, extremities, and pleura. Here, we report the MRI, FDG PET/CT, and FAPI PET/CT findings of a rare prostate solitary fibrous tumor. A 57-year-old man was pathologically diagnosed with a solitary fibrous tumor. To detect any systemic metastases or other primary lesions, the patient underwent FDG PET/CT and FAPI PET/CT examination sequentially. Mild FDG uptake was observed in the primary prostatic lesion, but there was a significant uptake of FAPI in the prostate. This case highlighted that FAPI PET/CT may outperform FDG PET/CT in identifying solitary fibrous tumors.


  • Open Access

    Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine

    by Chao Yang, Xian Sun, Hengbing Wang, Ting Lu, Keqing Wu, Yusheng Guan, Jing Tang, Jian Liang, Rongli Sun, Zhongying Guo, et al.

    Bladder cancer (BCa) is a common urinary tract malignancy with frequent recurrences after initial resection. Submucosal injection of gemcitabine prior to transurethral resection of bladder tumor (TURBT) may prevent recurrence of urothelial cancer. However, the underlying mechanism remains unknown. In the present study, ultra‑performance liquid chromatography Q‑Exactive mass spectrometry was used to profile tissue metabolites from 12 BCa patients. The 48 samples included pre‑ and post‑gemcitabine treatment BCa tissues, as well as adjacent normal tissues. Principal component analysis (PCA) revealed that the metabolic profiles of pre‑gemcitabine BCa tissues differed significantly from those of pre‑gemcitabine normal tissues. A total of 34 significantly altered metabolites were further analyzed. Pathway analysis using MetaboAnalyst identified three metabolic pathways closely associated with BCa, including glutathione, purine and thiamine metabolism, while glutathione metabolism was also identified by the enrichment analysis using MetaboAnalyst. In search of the possible targets of gemcitabine, metabolite profiles were compared between the pre‑gemcitabine normal and post‑gemcitabine BCa tissues. Among the 34 metabolites associated with BCa, the levels of bilirubin and retinal recovered in BCa tissues treated with gemcitabine. When comparing normal bladder tissues with and without gemcitabine treatment, among the 34 metabolites associated with BCa, it was observed that histamine change may be associated with the prevention of relapse, whereas thiamine change may be involved in possible side effects. Therefore, by employing a hypothesis‑free tissue‑based metabolomics study, the present study investigated the metabolic signatures of BCa and found that bilirubin and retinal may be involved in the mechanism underlying the biomolecular action of submucosal injection of gemcitabine in urothelial BCa.